This is a summary of the European public assessment report (EPAR) for Varuby. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Varuby.
For practical information about using Varuby, patients should read the package leaflet or contact their doctor or pharmacist.
Varuby : EPAR - Summary for the public (PDF/76.37 KB)
First published: 31/05/2017
Last updated: 31/05/2017
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
TESARO Bio Netherlands B.V.
|Date of issue of marketing authorisation valid throughout the European Union||
11/03/2019 Varuby - EMEA/H/C/004196 - T/0015
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Antiemetics and antinauseants
Prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.
Varuby is given as part of combination therapy.